Shi Ying-Hui, Shi Chang-He
Department of Microbiology, Centers for Disease Control and Prevention of Qingdao, Qingdao, Shandong Province, China.
World J Gastroenterol. 2009 Jul 7;15(25):3099-105. doi: 10.3748/wjg.15.3099.
Hepatitis B virus (HBV) is a common viral pathogen that causes a substantial health burden worldwide. Remarkable progress has been made in our understanding of the natural stages of chronic HBV infection. A dynamic balance between viral replication and host immune response is pivotal to the pathogenesis of liver disease. Knowledge of the HBV genome organization and replication cycle can unravel HBV genotypes and molecular variants, which contribute to the heterogeneity in outcome of chronic HBV infection. Most HBV infections are spontaneously resolved in immunocompetent adults, whereas they become chronic in most neonates and infants at a great risk of developing complications such as cirrhosis and hepatocellular carcinoma (HCC). Those with chronic HBV infection may present in one of the four phases of infection: immune tolerance, immune clearance [hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB)], inactive carrier state, and reactivation (HBeAg-negative CHB). Understanding the dynamic nature of chronic HBV infection is crucial in the management of HBV carriers. Long-term monitoring and optimal timing of antiviral therapy for chronic HBV infection help to prevent progression of HBV-related liver disease to its later stage, particularly in patients with higher risk markers of HCC, such as serum DNA concentration, HBeAg status, serum aminotransferase, HBV genotypes, and pre-core or core mutants.
乙型肝炎病毒(HBV)是一种常见的病毒病原体,在全球范围内造成了沉重的健康负担。我们对慢性HBV感染的自然阶段的认识取得了显著进展。病毒复制与宿主免疫反应之间的动态平衡对于肝病的发病机制至关重要。了解HBV基因组结构和复制周期有助于揭示HBV基因型和分子变异,这些因素导致了慢性HBV感染结局的异质性。大多数HBV感染在免疫功能正常的成年人中可自发清除,而在大多数新生儿和婴儿中则会发展为慢性感染,并有很大风险发生肝硬化和肝细胞癌(HCC)等并发症。慢性HBV感染患者可能处于感染的四个阶段之一:免疫耐受、免疫清除[乙肝e抗原(HBeAg)阳性慢性乙型肝炎(CHB)]、非活动携带者状态和再激活(HBeAg阴性CHB)。了解慢性HBV感染的动态特性对于管理HBV携带者至关重要。对慢性HBV感染进行长期监测并把握抗病毒治疗的最佳时机,有助于预防HBV相关肝病进展至晚期,尤其是对于具有较高HCC风险标志物的患者,如血清DNA浓度、HBeAg状态、血清转氨酶、HBV基因型以及前核心或核心突变体。